6-K 1 ea0266356-6k_ascentage.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of November 2025

 

Commission File Number: 001-42484

 

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

 

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

 

EXPLANATORY NOTE

 

On November 19, 2025, Ascentage Pharma Group International issued a press release entitled “Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025”. A copy of the press release is furnished as Exhibit 99.1 to this Report.

 

1

 

 

INDEX TO EXHIBITS

 

Exhibit    
Number   Exhibit Title
     
99.1   Press Release dated November 19, 2025

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ASCENTAGE PHARMA GROUP INTERNATIONAL
   
Date: November 19, 2025 /s/ Dajun Yang
  Name:  Dajun Yang
  Title: Chief Executive Officer

 

3